Mar 30, 2016 7:40am EDT U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
Mar 17, 2016 7:56am EDT Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015
Mar 02, 2016 10:30am EST Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference
Feb 17, 2016 2:08pm EST Adaptimmune to Present at the RBC Capital Markets Global Healthcare Conference
Feb 09, 2016 11:59am EST U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma
Feb 02, 2016 8:21am EST Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)
Jan 07, 2016 9:00am EST Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications
